The COVID Project
The record
- Jurisdiction
- United States (federal); Drug Enforcement Administration and SAMHSA
- Level
- Federal
- Authority
- 21 U.S.C. 802(54)(G), 821, 823, 829, 871(b)
- Issued
- 2023-05-10 May 10, 2023
- Effective
- 2023-05-11 through 2024-11-11 (read as 2023-05-11)
- End
- 2024-11-11 (further extended by 88 Fed. Reg. 69879 and 89 Fed. Reg. 91253) (read as 2024-11-11)
- In force
- May 11, 2023 to Nov. 11, 2024
- Limitation types
- Telework mandateHealth care orders
- Addressees
- DEA-registered practitioners
- Functions reached
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
The full set of telemedicine flexibilities regarding prescription of controlled medications as were in place during the COVID-19 PHE will remain in place through November 11, 2023.... it extends, through November 11, 2023, the telemedicine flexibilities that have been in place since March 2020 for prescribing controlled medications via the practice of telemedicine.
Enforcement
Controlled Substances Act
Notes
Post-period instrument saved for its recital that the March 2020 telemedicine flexibilities remained continuously in place.